# Delaying cardiac aging: potential mechanisms centered on PANoptosis and targeted intervention strategies

## TL;DR

This review explores how targeting PANoptosis, a cell death pathway, could help delay cardiac aging and improve heart health in older populations.

## Contribution

The paper introduces PANoptosis as a novel mechanism in cardiac aging and highlights targeted intervention strategies for therapeutic development.

## Key findings

- PANoptosis contributes to cardiac aging by promoting cardiomyocyte loss and inflammation.
- Interventions targeting PANoptosis show therapeutic potential in preclinical studies.
- Regulatory networks of PANoptosis provide a foundation for developing new therapies.

## Abstract

As the vital power organ of the human body, the health of the heart directly determines an individual's quality of life and longevity. With the accelerating global aging population, cardiac aging-related diseases have become a major public health threat. Although existing interventions (e.g., senolytics) can delay cardiac aging to some extent, their efficacy remains limited, necessitating the exploration of novel mechanisms to develop more effective therapeutic strategies. In recent years, PANoptosis—an integrated cell death pathway—has emerged as a new research focus in cardiac aging. It may contribute to cardiac functional decline by accelerating cardiomyocyte loss, fibrosis, and chronic inflammation. Targeting PANoptosis-based intervention strategies (e.g., gene editing, RNAi, combination therapy, and novel delivery systems) has demonstrated significant therapeutic potential, offering new preclinical avenues to delay or alleviate cardiac aging. This review summarizes the molecular mechanisms and roles of PANoptosis in cardiac aging, including its regulatory networks, key evidence driving cardiac aging, and targeted intervention strategies, thereby providing a theoretical foundation for developing PANoptosis-targeted therapies against cardiac aging.